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Background and Aims: Hepatitis B virus infection is a serious global health 
problem and causes life-threatening liver disease. In particular, genotype C shows 
high prevalence and sever liver disease compared with other genotypes. However, 
the underlying mechanisms regarding virological traits still remain unclear. This 
study investigated the clinical factors and capacity to modulate Type I interferon 
(IFN-I) between two HBV polymerase polymorphisms rt269L and rt269I in 
genotype C. 
 
Methods: The clinical factors between rt269L and rt269I in 220 Korean chronic 
patients with genotype C2 infections were compared. The prevalence of preC 
mutations between rt269L and rt269I was compared using this cohort study and the 
GenBank database. For in vitro study, plasmid DNA encoding HBV genome were 
transiently transfected into hepatocytes, and HBV virions were infected using 
HepG2-hNTCP-C4 and HepaRG systems. In addition, hydrodynamic injection of 
HBV genome into mice tail were conducted for in vivo experiments.  
 
Results: The clinical cohort study indicated that rt269I was related to HBV e 
antigen (HBeAg) negative serostatus, lower levels of HBV DNA and HBsAg, and 
disease progression compared to rt269L. Furthermore, the epidemiological study 
 II 
showed that HBeAg negative infections of rt269I were attributed to a higher 
frequency of preC mutations at 1896 (G to A). In vitro and in vivo study also 
suggested that rt269I caused mitochondrial stress mediated STING dependent IFN-
I production, resulting in decreasing HBV replication via the induction of heme-
oxygenase-1. In addition, I also found that rt269I enhanced iNOS mediated NO 
production in an IFN-I dependent manner.  
 
Conclusion: In this study, I found that there are two polymorphisms at 
polymerase RT region, rt269L and rt269I, in patients infected with genotype C, 
which is only found in genotype C. These data demonstrated that rt269I can 
contribute to HBeAg negative infections and liver disease progression in chronic 
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INTRODUCTION 
 
Viral hepatitis is a high-risk global health issue, leading to chronic infection that 
can cause fibrosis, liver cirrhosis (LC), hepatocellular carcinoma (HCC), and liver failure 
[1]. Compared to the life-threating infectious diseases, the number of deaths caused by 
viral hepatitis was comparable to deaths caused by tuberculosis, and higher than those 
caused by Human Immunodeficiency virus (HIV) and malaria. The number of deaths 
caused by HIV, tuberculosis, and malaria has declined, while the mortality caused by viral 
hepatitis has increased by 22% since 2000 [2]. Of the viral hepatitis, it was estimated that 
350 million patients were chronically infected with hepatitis B virus (HBV) and 900,000 
patients died [3], that accounted for 66% of the deaths caused by viral hepatitis. 
Furthermore, HBV infection is also a major public health problem in Korea. In 2015, it 
reported that liver cancer led the number of second-highest mortality among the entire 
cancer patients, and HBV infection accounted for 74% of the cause of liver cancer [4]. 
Although vaccines and therapeutic agents are currently available against HBV, the number 
of deaths caused by HBV has increased worldwide [5]. In these reasons, the alternative 
targets to HBV life cycle should be elucidated to effectively cure them.  
HBV is an enveloped and partially double-stranded DNA virus, a species of genus 
Orthohepadnavirus and a member of the Hepadnaviridae family of viruses. The infectious 
virus particle, called Dane particle, is 42 nm in diameter. The HBV genome that is 
approximately 3.2 kb in length, and consists of four open reading frames (ORFs): surface 
antigens (S), core proteins (Cp), polymerase (Pol), and X proteins (X) [6]. Hepatitis B 
surface antigen (HBsAg) consists of small, medium and large protein, and Pol consists of 
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terminal protein (TP), spacer, reverse transcriptase (RT) and RNase H. HBV has tissue 
tropism to hepatocytes, and the viral life cycle starts when HBV attaches to cell surface 
receptor sodium taurocholate cotransporting polypeptide (NTCP) that is mostly found in 
the sinusoidal membrane of hepatocytes [7]. Following endocytosis, the viral memvrane 
fuses with the cell membrane, releasing the nucleocapsid containing the relaxed circular 
DNA (rcDNA) or double-stranded linear DNA (dsDNA) into cytoplasm and transferred to 
the nucleus [8]. After infecting the hepatocytes, the genomes from HBV are converted to 
covalently closed circular DNA (cccDNA) by host enzymes [9]. The cccDNA serves as a 
template to transcript sub-genomic RNA and pre-genomic RNA (pgRNA) that translate 
Cp and Pol. The synthesized Cp and Pol are encapsidated and are used to replicate more 
copies of genomes via reverse transcription activity of Pol. Surface and X proteins were 
translated from sub-genomic RNA and enveloped with nucleocapsid in Golgi-complex and 
finally released from the infected hepatocytes [9]. There are various therapeutic agents 
targeting in HBV life cycle and modulating virus-host interaction, such as nucleot(s)ide 
analogue agents and interferon-a [10]. HBV cccDNA is related to persistent infection 
cannot be completely eradicated by nucleot(s)ide analogue agents [11]. In these reasons, 
epigenetic regulation is necessary for the complete viral clearance from chronic hepatitis 
B (CHB) patients [12], that modulates innate immune response such as Type I IFN (IFN-
I). 
In pathogenesis, chronic HBV infection causes increased intracellular reactive 
oxygen species (ROS) and oxidative stress in host [13]. The increased levels of ROS 
induce a general inflammatory response that leads to a further increase in ROS and 
oxidative DNA damage, which cause progression of liver disease [14, 15]. In the responses 
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to ROS, heme-oxygenase-1 (HO-1) is strongly up-regulated and plays role in the 
cytoprotective enzyme via degradation of heme to generate carbon monoxide (CO), ferrous 
iron (Fe2+), and biliverdin that is subsequently converted to bilirubin by biliverdin 
reductase [16]. Therefore, HO-1 interferes with chronic inflammation and enhances 
antiviral properties by its three active products [17]. In addition, HO-1 interacts with 
interferon regulatory factor-3 (IRF-3) to activate IFN-I response that is the first defense 
mechanism against viral infection [18]. 
IFN-I are large subgroup of interferon proteins and include IFN-α, -β, -ω, -κ, -τ, 
and -ζ, which bind to heterodimeric transmembrane receptor complex known as IFN-α 
receptors (IFNAR) that consist of IFNAR1 and IFNAR2 chains. IFN-I are produced by 
various cell types to elicit anti-viral responses [19] that are initiated after host recognition 
of viral pathogen-associated molecular patterns (PAMPs) through pattern recognition 
receptors (PRRs) [20] such as toll-like receptor (TLR), retinoic acid-inducible gene I (RIG-
I)-like receptor, cytosolic DNA sensing receptor. They converge at the level of 
TBK1/IKKe that can phosphorylate transcription factors such as IRF3 and IRF7 to induce 
IFN-I [21]. In the second phase, the secreted IFN-I bind to IFNAR that triggers 
oligomerization and tyrosine phosphorylation of Janus kinase-1 (JAK-1) and tyrosine 
kinase-2 (TYK-2), which phosphorylate signal transducer and activator of transcription 
(STAT)-1 and -2 [22]. The activated STAT-1 and -2 heterodimerize with IRF-3 that 
translocate into the nucleus, where they bind to the interferon-stimulated response element 
(IRSE) and initiate transcription of ISGs [23]. In addition, IFN-I subsequently regulate 
other viral defense responses such as inducible nitric oxide synthase (iNOS) and APOBEC 
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enzymes [24, 25], which induce mutations such tryptophan codon (TGG) to a stop codon 
(TAG) on virus genome [26, 27] .  
Cytosolic DNA is related to viral infection, invasion of intracellular bacteria, and 
damaged DNA as a cell intrinsic danger signal, which are mediated by cytosolic receptor 
cGAMP synthase (cGAS)-stimulator of interferon genes (STING) to induce IFN-I 
response [28]. Upon binding DNA, cGAS triggers reaction of GTP and ATP to form cyclic 
GMP-AMP (cGAMP) that binds to STING. STING phosphorylates IRF3 that can 
translocate into the nucleus to transcript ISGs [29]. This pathway plays a critical role in 
mediating immune defense against double-stranded DNA viruses. Hepatitis B virus DNA 
can be recognized by cGAS [30], and HBV pgRNA can be recognized by RIG-I, leading 
to induction of type I IFN [31]. However, HBV has developed various strategies to evade 
host IFN-I dependent innate immunity [32]. It has been reported that some HBV proteins 
such as HBsAg, HBV e antigen (HBeAg), and HBV virions can lead to inhibit TLR 
mediated IFN-I production [33]. In RNA sensing pathways, HBxAg and Pol can also 
negatively regulate RIG-I mediated antiviral responses [34, 35]. In addition, it has also 
been reported that HBV Pol can block IFN-I dependent antiviral pathways via the 
inhibition of STING dependent cytosolic DNA sensing pathways [36].  
On the basis of an 8% divergence in HBV genome sequences, HBV has been 
characterized into 10 genotypes as A-J [37]. Various studies on HBV genotypes have 
reported that they have distinct pathogenic potential as well as distinct geographic and 
ethnic distributions [38], showing genotype A is predominant in sub-Saharan Africa, 
Northern Europe, and genotype D is common in Africa, Europe, Mediterranean countries. 
Among the 10 genotypes, genotypes B and C are widespread in Asia, being estimated more 
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than eighty-seven percent of patients. Although genotype B and C were showed in same 
high-endemic region by perinatal or vertical infection, two genotypes lead to distinctly 
different clinical outcomes [39]. Compared to genotype B, genotype C showed high HBV 
replication capacity, with high levels of HBV DNA in the serum [40, 41]. In addition, the 
tendency of chronicity was higher and more frequently developed into liver cirrhosis (LC) 
and hepatocellular carcinoma (HCC) in patients with genotype C than genotype B [42]. 
Furthermore, genotype C has low frequency of the well-known mutation, A1896 on pre-
core region that stop translation of HBeAg, which can lead HBeAg positivity, and high 
frequency of basal core promoter T1762/A1764 that can cause severe disease progression 
and drug resistance [43]. These mutations can finally elicit strong resistance against 
nucleos(t)ide analogs and interferon therapy. However, the underlying mechanisms 
regarding distinct clinical and virological traits and distinct responses to IFN therapy 
between genotype C and genotype B remain unknown. Because genotype C has the great 
portion of chronic patients and worse disease progression, elucidation of their pathogenesis 
could lead to reduce various liver disease caused by HBV.  
In previous studies, it has introduced that mutations on HBV genome can be 
highly associated with their pathogenesis of genotype C than other genotypes, such as 
P5H/L/T on C, W182* on S, and V5M and H94Y on X protein [44]. In addition, some 
mutations in the reverse transcriptase (RT) region of Pol related to HCC from genotype C 
infected patients [rtM80I, rtN139K/T/H and rtM204I/V] [45]. Although Pol is the protein 
that can not only regulate HBV genome replication but also overlapped with small surface 
antigen region, the mutation of them has not well studied. Furthermore, there are various 
anti-HBV drugs to block the Pol function, however, the effective drugs are still required. 
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Because Pol is essential for viral replication and effective target to develop anti-HBV drug, 
I tried to verify the correlation between mutations and disease progression in genotype C. 
In addition to HBV mutations, it has been reported that there are several genotype 
dependent polymorphisms in HBV RT regions, which are generally defined as having a 
frequency less than 10% versus wild type (Table 1). Of these, there are two 
polymorphisms at the Pol-269 site, rt269L (57.2%) and rt269I (42.8%), in patients with 
genotype C, in which two types are present with an almost similar ratio, but only rt269I is 
present as a major wild type in other genotypes. 
In this study, I sought to investigate the clinical factors and capacity to modulate 
IFN-I between two HBV polymorphisms, rt269L and rt269I, in genotype C infected CHB 
patients. In vivo and in vitro study, I verified that rt269I infection causes mitochondrial 
stress that activates IFN-I signaling via cGAS-STING pathway. The activated IFN-I 
upregulate iNOS and APOBEC3G in the infected hepatocytes, suggesting higher 
frequency of G1896A mutation and HBeAg negative infection. These results suggested 
that the presence of two HBV Pol RT polymorphisms distinct only in HBV genotype C 
may play a very pivotal role in viral phenotypes, clinical outcomes, and worse responses 
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MATERIALS AND METHODS 
 
1. Patients 
 For this study, serum samples were collected from 410 patients chronically infected 
with HBV and the amino acid at 269th on RT region was identified by direct sequencing 
method. In 190 patients of these, their polymorphisms could not be identified by 
sequencing analysis due to lack of sensitivity. However, 220 patients could be identified 
into their polymorphism, rt269L or rt269I types and selected for this study. To elucidate 
the correlation between the polymorphism of 269th amino acid and the characteristics of 
disease, their clinical factors and polymerase RT regions were assessed. This report was 
approved by the Institutional Review Board of Konkuk University Hospital (KUH-
1010544) and Seoul National University Hospital (IRB-1808-067-965). 
 
2. HBV DNA extraction and PCR amplification for polymerase RT region 
For this cohort study, HBV DNA was extracted from the serum of patients using a 
QIAamp DNA Blood Mini kit (QIAGEN, Hilden, Germany) and dissolved in Tris-EDTA 
buffer (10 mM Tris-HCl, 1 mM ethylenediaminetetraacetic acid, pH 8.0). First-round PCR 
was performed using primers POL-RT1 and the amplicon was used as templates for 
second-round PCR using primers. The PCR products were subject to direct sequencing 
analysis.  
 
3. HBV genotyping 
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The 1,032-bp polymerase RT sequences were examined by direct sequencing and 
were compared to the sequences of the reference strains representing each of the genotypes 
(A-H including the C strains) obtained from GenBank. The sequences of the RT region 
were compared via phylogenetic/molecular evolutionary analysis using MEGA version 7.0 
and MrBayes version 3.2.7. Phylogenetic trees were obtained using the Maximum-
likelihood method (1,000 bootstrap replicates) and Bayesian method, and the mean genetic 
distances were estimated using Kimura two-parameter model.  
 
4. Plasmid and site-directed mutagenesis 
The pHBV-1.2x (GenBank accession No. AY641558) containing genotype C HBV 
full-length genome was used for site-directed mutagenesis to generate polymerase RT 
mutant DNA constructs using an i-pfu kit (iNtRON, Seongnam, Korea). Mutagenesis was 
performed using the primers rt269I based on rt269L construct. To exclude CMV promoter, 
HBV full genome constructs were cut by restriction enzymes and prepared for linear 
formed genome.  
 
5. Cell culture and transfection 
Human hepatocellular carcinoma HepG2 cells and mouse hepatoma Hepa-1c1c7 
purchased from the Korean Cell Line Bank (KCLB, Seoul, South Korea) were grown in 
minimum essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 
100 µg/ml of penicillin-streptomycin, and 25 mM HEPES at 37℃ in a humidified 
environment containing 5% CO2. pHBV-1.2x containing genotype C HBV full-length 
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genome (2.5 µg) was transiently transfected using Lipofectamine 3000 (Invitrogen, 
Carlsbad, CA, USA). To normalize the transfection efficacy, pSV-b-Galactosidase (0.25 
µg) was co-transfected, and the enzyme assay was accompanied using b-Galactosidase 
Enzyme Assay System with Reporter Lysis buffer (Promega, Madison, WI, USA), 
following the manufacturers’ protocol. 
 
6. In vivo assay and hydrodynamic injection 
Female C57BL/6 mice (7 weeks old) were hydrodynamically tail-vein injected with 
HBV DNA (10 µg) per 8% of mouse body weight within 30 seconds. All of the animal 
experiments were approved by the Institutional Animal Care and Use Committee (IACUC) 
of Seoul National University College of Medicine (SNU-170308). Mice were sacrificed 
on 4, 7, and 16 days after HBV-encoding DNA injection, and liver and serum were used 
to analyze gene expression of ISGs and HBV viral factor, respectively.  
 
7. Enzyme-linked immunosorbent  
To measure the HBV antigens in the blood serum or culture supernatant, ELISA was 
performed for HBsAg (Biokit, Barcelona, Spain) and HBeAg (AccuDiag, Oceanside, CA, 
USA) according to the manufacturers’ instructions. The concentration of mouse and 
human IFN-b was measured with ELISA kit purchased from Biolegend (San Diego, CA, 
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8. Covalently closed circular DNA extraction and real-time polymerase chain 
reaction  
The pHBV-1.2x with rt269L or rt269I were digested with restriction enzyme SmaI to 
remove CMV promoter, and the linear DNA (2.5 µg) were transfected using lipofectamine 
3000 following manufacture’s instruction. The transfected cells were lysed with lysis 
buffer (50 mM Tris-HCl, pH7.4, l mM EDTA, and 1% NP-40), and the nuclei were 
collected via centrifugation and incubated with nucleus lysis buffer (10 mM Tris-10 mM 
Tris-HCl, 10 mM EDTA, 150 mM NaCl, 0.5% SDS, and 0.5 mg/ml protein K). The nucleic 
acids were purified via ethanol precipitation and treated with 10 U Plasmid-Safe ATD 
dependent DNase I (PSAD, Epicentre, Madison, WI, USA). The cccDNA was purified by 
PCI and ethanol precipitation and quantified via real-time PCR using SYBR and primers 
cccDNA-F and cccDNA-R (Table 2).  
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Table 2. PCR primers used for this study. 
Primers Forward  Reverse 
POL-RT1 CAG CCT ACT CCC ATC TCT CCA CCT CTA AG GCT CCA GAC CGG CTG CGA GC 
POL-RT2 CCT CAG GCC ATG CAG TGG AA GTA TGG ATC GGC AGA GGA GC 
rt269I-C GAA CAT ATT GTA CAA AAA ATC AAG CAA TGT TTT CGG AAA TTT CCG AAA ACA TTG CTT GAT TTT TTG TAC AAT ATG TTC 
pgRNA GGT CCC CTA GAA GAA GAA CTC CCT CAT TGA GAT TCC CGA GAT TGA GAT 
cccDNA CCG TCT GTG CCT TCT CAT CAC AGC TTG GAG GCT TGA AC 
mouse APOBEC3G CCC CTG TTT CGA ATG TGC A TGG TGT GTA GCC AGG AAC CTT 
mouse IFN-α TCT GAT GCA GCA GGT GGG AGG GCT CTC CAG ACT TCT GCT CTG 
mouse IFN-β GCA CTG GGT GGA ATG AGA CT AGT GGA GAG CAG TTG AGG ACA 
mouse iNOS GGC AGC CTG TGA GAC CTT TG GCA TTG GAA GTG AAG CGT TTC 
human APOBEC3G ACA ACA GGT AGT AGG CGA CA CCA ACA GTG CTG AAA TTC GTC ATA 
human IFN-β AGC AAG TTG TAG CTC ATG GAA ACA ACA GGT AGT AGG CGA CA 
human RIG-I GGA CGT GGC AAA ACA AAT CAG GCA ATG TCA ATG CCT TCA TCA 
human ISG-15 AGC TCC ATG TCG GTG TCA G GAA GGT CAG CCA GAA CAG GT 
human HO-1 ACA TCT ATG TGG CCC TGG AG TGT TGG GGA AGG TGA AGA AG 
human iNOS GTT CTC AAG GCA CAG GTC TC GCA GGT CAC TTA TGT CAC TTA TC 
mouse/human 18S rRNA AGT CCC TGC CCT TTG TAC ACA CGA TCC GAG GGC CTC ACT A 
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9. Total RNA extraction and real-time polymerase chain reaction (qRT-PCR) 
Total RNA was extracted from the transfected cells or mouse liver tissue using TRIzol 
and the target genes were amplified using SensiFAST SYBR Lo-ROX One-Step kits 
(BioLine, London, UK). The transcription level was analyzed using qRT-PCR with sets of 
primers (Table 2) and housekeeping gene 18S ribosomal RNA was used as an internal 
control. 
 
10. IFN-I luciferase reporter assay 
Cell culture supernatants from transfected cells were overlaid on top of HEK293 IFN 
reporter cells containing ISRE-luciferase construct [46] and incubated for 4 hours. The 
reporter cells were lysed in passive lysis buffer (Promega, Madison, WI, USA) for 30 
minutes at room temperature, mixed with firefly luciferin substrate (Promega, Madison, 
WI, USA), and measured using an illuminometer (Beckman Coulter Inc., Fullerton, CA, 
USA).  
 
11. IFN-I signal block assay 
HepG2 cells were pre-treated with 10 µg of anti-IFNAR2 antibody (PBL assay 
Science, Piscataway, NJ, USA) and AZD1480 (Sigma, St. Louis, MO, USA) in MEM 
supplemented with 2% of FBS and transfected with pHBV-1.2x DNA constructs. STING-
siRNA were co-transfected with pHBV-1.2x DNA constructs, following the manufacturers’ 
procedures (Santa Cruz Biotechnology, Dallas, TX, USA, and Thermo-Fisher Scientific, 
Waltham, MA, USA).  
 
 - 14 - 
12. Preparation of HBV from transiently transfected cells and Infection assay  
For an infection study, culture supernatant of HepG2 cells, transiently transfected with 
1.2x-rt269L or rt269I type of HBV plasmid, was collected. The supernatant was cleared 
through a sterile 0.45-µm pore size filter and precipitated with 6% polyethylene glycol 
(PEG) 8000 overnight. The media were ultracentrifuged and the collected pallet was 
resuspended in PBS containing 15-25% FCS. After quantification by qPCR, 3 X 109 HBV 
genome equivalent per milliliter was aliquoted and stored at -80 ℃. HepaRG and HepG2-
hNTCP-C4 cells were seeded in 12-well plates. Infection assay was performed with the 
concentrated virus in the presence of 4% PEG8000 at 37 ℃ for 20h. HepaRG was 
purchased from BIOPREDIC International (HPR116) and HepG2-hNTCP-C4 was kindly 
provided by Dr. Koichi Watashi (National Institute of Infectious Disease, Tokyo, Japan). 
 
13. Flow cytometry and Confocal analysis 
The mtROS were stained with MitoSox (5 µM), and analyzed by flow cytometry 
(LSRII, Becton Dickinson) and confocal microscope (Confocal-A1, Nikon). DAPI was 
used to stain nuclei and the cells were mounted in mounting medium (VECTASHIELD 
Antifade Mounting Medium, H-1000). The images were captured using a 100x oil 
immersion objective lens.   
 
14. 8-OHdG ELISA assay 
Genomic DNA was extracted from the transfected cells using QIAamp Blood DNA 
extraction kit (QIAGEN, Hilden, Germany). For the detection of 8-hydroxy-2′-
deoxyguanosine (8-OHdG) activity, a competitive ELISA for 8-OHdG analysis kit 
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(OxiSelect Oxidative DNA Damage ELISA kit, Cell Biolabs, San Diego, CA, USA) was 
used according to the manufacture's protocol. 
 
15. Measurement of NO2- and NO3- levels  
The produced NO was measured using culture supernatants from the transfected cells 
using a colorimetric Nitrite/Nitrate Assay Kit (Sigma, St. Louis, MO, USA) according to 
the manufacturer’s instructions, and measured the absorbance at 540 nm in microplate 
reader (TECAN). 
 
16. Statistical Analyses 
For the cohort study, statistical analysis was performed using SPSS Software (IBM 
SPSS version 23.0.0.0 Inc., Chicago, USA). Categorical variables were analyzed using 
Multivariate Analysis of Variance (MANOVA). Independent t-test was used to compare 
continuous variables. Tests were two-sided.  
Experimental data were analyzed using Graphpad Prims 5 (GraphPad Software, La Jolla, 
CA, USA). All experiments were independently repeated three times and the statistical 
analyses were indicated in the figure legends. The p value of statistical significance was 
set at either; *p < 0.05; **p < 0.01; ***p < 0.001. 
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RESULTS 
 
1. rt269I was related to enhanced disease progression in a Korean cohort with 
genotype C infections. 
In the web page “HBV RT: Mutation prevalence according to genotype and treatment” 
(https://hivdb.stanford.edu/HBV/DB/cgi-bin/MutPrevByGenotypeRxHBV.cgi.), the 
mutation prevalence or polymorphisms of the entire HBV RT region were analyzed 
according to the genotypes and antiviral drug treatments (Table 1). A comparison of all of 
the 344 codons of RT found one unique genotype C site at the 269th codon of RT, in which 
both types, one for rt269L encoding leucine and the other for rt269I encoding isoleucine, 
were present in patients infected with genotype C at frequencies of 57.2% and 42.8%, 
respectively. Although rt269 codon is located at the outer region of overlapped HBsAg, 
polymorphism of rt269 cannot lead to HBsAg amino acid change, not affecting the 
performance of the HBsAg kit or immunoblotting data. There were no other 
polymorphisms in patients infected with genotype C exceeding 10% of the total frequency. 
Therefore, I postulated that the polymorphism at the 269th codon of RT may play an 
important role in the clinical outcomes and pathogenesis of genotype C infections. To 
address this issue, I analyzed the 269th codon polymorphisms of 220 patients in the Korean 
cohort with genotype C via direct sequencing of the RT region (Figure 1) and compared 
their clinical factors between rt269L and rt269I.    
Overall, 138 patients (62.7%) and 82 patients (37.3%) were infected with rt269L and 
rt269I, respectively (Table 3). Interestingly, I found there were several patients mixed with 
 - 17 - 
both rt269L and rt269I in sequencing data, maybe due to quasi species generation. In these 
cases, I determined their polymorphisms types into one reflecting dominance in 
sequencing data. 
 Interestingly, there were distinct disparities in some clinical factors between the patients 
with rt269L and rt269I (Table 3). The patients with rt269I had significantly lower levels 
of HBV DNA and HBsAg, HBeAg negative infection, and liver disease progression based 
on immune response against HBV [47]. These data suggested that both rt269L and rt269I 
on the RT region may be key factors determining clinical outcomes regarding disease 
progression and HBeAg negative infection in genotype C infected patients.



























Figure 1. Phylogenetic analyses of 1,032-bp polymerase RT sequences showed that 
the representative 20 patients used in cohort study belonged to genotype C. The RT 
sequences were aligned using MEGA7 and the phylogenetic trees were constructed using 
Bayesian (A) and Maximum likelihood (B) method. The bootstrap values were calculated 
from 1,000 replications, and burn in was set at 25% of samples. The bars indicate numbers 
of substitutions per nucleotide position. 
B 
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Table 3. Comparison of the clinical features between patients infected with the two types 
of genotype C, rt269L and rt269I. 
CH, chronic hepatitis; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine 
transaminase. 
†1. Immune-tolerant. 2. Immune-clearance. 3. HBeAg negative CHB. 4. Inactive carrier. 
Continuous variables were tested using the chi-squared test and categorical variables were analyzed using 
Student’s t-test. ns, non-significant; *p<0.05; **p<0.01; ***p<0.001
Clinical factors rt269L (n=138) rt269I (n=82) p-value 
CH:HCC 92:46 46:36 ns 
Sex, men 63.04% 64.63% ns 
HBeAg negative  28.99% 52.44% ** 
AST/ALT 1.16±0.78 1.42±1.43 ns 
HBV-DNA (log10 copies/ml) 6.47±1.71 5.75±1.62 ** 
HBsAg (log10 IU/ml) 3.74±0.61 3.41±0.71 *** 
Age (years) 42.04±12.45 45.89±12.61 * 
Bilirubin (mg/dL) 0.99±0.91 1.37±.1.71 * 
Albumin (g/dL) 4.01±0.58 3.95±0.63 ns 
Prothrombin time (INR) 1.11±0.18 1.14±0.18 ns 
Platelet (109/L) 169.93±63.74 168.43±81.93 ns 
Fibrosis-4 score 4.05±7.96 4.45±5.42 ns 
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2. The higher frequency of preC mutation (G1896A) in patients with 
rt269I infections was responsible for the higher frequency of HBeAg 
negative infections.   
   Of the various HBV mutations, G1896A mutations on the pre-core region (preC 
mutation) and A1762T/G1764A double mutations on the basal core promoter (BCP) 
lead to HBeAg negative infection that are significantly related to liver disease 
progression [48]. To verify whether these mutations are associated with distinct 
clinical factors of genotype C infections between rt269L and rt269I, their mutation 
rates were compared not only to chronic infectious patients in the cohort study, but 
also to the reference strains in GenBank (Table 4). In double mutations in BCP, only 
the G1764A mutation, but not the A1762T, was significantly prevalent in patients 
with rt269I and in GenBank. In addition, the rate of G1986A preC mutation was 
significant higher in patients with rt269I (49.61%) than those with rt269L (28.83%, 
p<0.01). These results suggested that the high frequency of G1986A preC mutation 
is responsible for HBeAg negative infections in patients with genotype C rt269I 
infections.  
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Table 4. The frequencies of BCP and preC mutations between rt269L and rt269I in a Korean cohort and from reference strains. 
BCP, basal core promoter; preC, pre-core 
Continuous variables were tested using the chi-squared test. ns, non-significant; *p<0.05; **p<0.01; ***p<0.001
Mutation Nucleotide 
Clinical isolates  Reference strains 
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3. rt269I led to lower levels of HBV replication in vitro and in vivo 
experiments. 
   The clinical and epidemiologic data suggested there may be differences in the 
HBV replication capacity between rt269I and rt269L infections. To verify this 
hypothesis, I performed in vivo and in vitro study with genotype C HBV full genome 
constructs with leucine or isoleucine at the 269th amino acid on the RT region. HBV 
replications between rt269I and rt269L infections were analyzed via in vivo and in 
vitro studies. The secreted HBsAg and HBV DNA was greatly increased in the serum 
from the mice infected with rt269L. However, rt269I showed relatively lower HBV 
replication levels (Figure 2A and B). As shown in the in vivo study, the secreted 
HBsAg and HBeAg levels also decreased in HepG2 cells transfected with rt269I 
(Figure 3A and B). These replicative capacities were also examined in HepG2 cells 
via transient transfection of the linearized HBV DNA constructs (Figure 3C and D), 
in which CMV promoter was deleted [49]. Intracellular intermediates of HBV 
amplification were also examined by Southern blotting, which indicated that double-
stranded (DS) and single-stranded (SS) DNA were significantly reduced in rt269I at 
48 hours post-transfection. (Figure 4A). In addition, the HBV capsid form that is an 
intermediate of HBV amplification was significantly reduced in rt269I at 24 hours 
after transfection (Figure 4B). Similarly, rt269I also showed decreased pgRNA 
levels and cccDNA levels (Figure 4C and D). Together, I found that rt269I reduces 
HBsAg, HBeAg, capsid form, cccDNA, and pgRNA that is observed in HBV life 
cycle, compared to rt269L. 
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Figure 2. The viral replication of rt269I was restricted in vivo infection model. 
Both HBV-encoding DNA (10 µg) and pSV-b-Galactosidase (1 µg) was injected by 
hydrodynamic tail vein injection into C57BL/6 mice (n=5). (A) The secreted HBsAg 
in serum was measured by ELISA. (B) HBV DNA in serum were determined by 
qPCR and normalized with b-Galactosidase. Two-way ANOVA were used. *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 3. rt269I reduced viral replication in vitro analyses. (A and B) pHBV-
1.2x-rt269L and -rt269I were co-transfected with pSV-b-Galactosidase into HepG2 
cells and the replicative capacities were analyzed. The level of secreted HBsAg (A) 
and HBeAg (B) were detected using ELISA. (C and D) The plasmid DNA were 
restricted by SmaI digestion to remove CMV promoter. The linearized DNA was 
transiently transfected to HepG2 cells and the levels of secreted HBsAg (C) and 
HBeAg (D) were analyzed using ELISA. Data were normalized by b-Galactosidase 
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Figure 4. The viral replication of rt269I was reduced in vitro transient 
transfection system. pHBV-1.2x-rt269L and -rt269I were co-transfected with pSV-
b-Galactosidase into HepG2 cells and the replicative capacities were analyzed. (A) 
HBV DNA was compared via Southern blotting at 48 hours post-transfection. (B) 
Western blot analyses of intracellular capsid forms were performed by using anti-
HBcAg antibody on naïve gel at 24 hours after transfection. (C) The translation 
mediates pgRNAs were detected by qRT-PCR. (D) The linearized DNA was 
transiently transfected into HepG2 cells. The intermediates of transcripts cccDNA 
were determined using qPCR. Data were normalized to b-Galactosidase enzyme 
assay. Data represent mean±S.D. One- and two-way ANOVA were used. *p<0.05, 
**p<0.01, ***p<0.001.  
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4. Hepatocytes activated IFN-I signaling against rt269I infection. 
Since IFN-I medicate antiviral effects by up-regulating APOBEC3G that 
hypermutate the HBV genome, I postulated that rt269I can enhance IFN-I mediated 
APOBEC3G signaling in infected hepatocytes and finally led to the higher frequency 
of G to A mutations on preC and BCP in patients with rt269I. To address this issue, 
I compared the gene expression of two representative IFN-I genes, INF-α and INF-
β, and interferon stimulated genes, ISG-15, RIG-I, and APOBEC3G that are induced 
by an IFN-I signal [50]. The mRNA levels of APOBEC3G, ISG-15, RIG-I, IFN-α, 
and IFN-β were significantly enhanced in the mice infected with rt269I on 4 days 
post-infection (Figure 5). In the same manner as shown in in vivo assays, the 
transcription levels of APOBEC3G and IFN-I-related genes, such as ISG-15, RIG-I, 
IFN-a, and IFN-β, were also induced in HepG2 cells transfected with rt269I at 12 
hours after transfection (Figure 6). To evaluate the upstream genes of the IFN-I 
signaling pathway, the activation or expression of STAT-1, IRF-3 and the STING 
genes [51, 52] were analyzed using Western blotting at 48 hours post-transfection 
(Figure 7A). rt269I activated STAT-1, IRF-3 and up-regulated STING in protein 
level. The secreted IFN-β was also assessed by ELISA and treating culture 
supernatant from the transfected cell onto HEK293 with luciferase construct under 
an interferon stimulated response element (ISRE) promoter [46]. As the results of 
activated IFN-I signal, the secreted IFN-I was significantly induced in cells 
transfected with rt269I at 24 hours post-transfection (Figure 7B and C). These 
results were consequently shown in the Huh-7 and Huh-7.5 cells defective in RIG-I 
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signaling at 24 hours after transfection (Figure 8A and B). It suggests that the 
enhancing effect of IFN-I found in rt269I may be due to pathways other than the 
RIG-I dependent pathway. Interestingly, rt269I enhanced IFN-I, even compared to 
genotype A wild type with the isoleucine at the 269th amino acid of RT at 24 hours 
after transfection (Figure 8C), suggesting that the trait capable of IFN-I induction 
as found in rt269I may be specific to genotype C. In addition, the HBV encoding 
DNA was also transfected into mouse hepatoma cell Hepa1c1c-7 and IFN-β was 
measured assessed by ELISA (Figure 8D). Consistent with human hepatocellular 
cells, mouse hepatocytes transfected with rt269I produced enhanced IFN-β 
production, compared to rt269L. Together, the data indicated that rt269I enhances 
IFN-I production in hepatocytes. 



































































































 - 31 - 
 
Figure 5. rt269I enhanced IFN-I production in vivo assay. Both HBV-encoding 
DNA and pSV-b-Galactosidase were injected by hydrodynamic tail vein injection 
into C57BL/6 mice (n=5). The transcription level of APOBEC3G (A), ISG-15 (B), 
RIG-I (C), IFN-α (D), and IFN-β (E) were determined by qRT-PCR from mice 
hepatocytes on 4 days post-infection, and normalized with 18S rRNA and b-
Galactosidase. Data represent mean±S.D. One-way ANOVA were used. *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 6. Hepatocytes increased transcription level of IFN-I against rt269I 
infection. HepG2 cells were co-transfected with HBV DNA and pSV-b-
Galactosidase, and the expression levels of IFN-I-related genes, APOBEC3G (A), 
ISG-15 (B), RIG-I (C), IFN-α (D), and IFN-β (E), were assessed. The mRNA level 
of IFN-I-related genes was determined using qRT-PCR at 12 hours after transfection, 
and data were normalized to 18S rRNA. Data represent mean±S.D. One-way 
ANOVA were used. *p<0.05, **p<0.01, ***p<0.001.  
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Figure 7. HepG2 cells activated IFN-I signaling pathway and produced INF-I 
against rt269I. pHBV-1.2x-rt269L and -rt269I were co-transfected with pSV-b-
Galactosidase into HepG2 cells. (A) The upstream proteins of the IFN-I signaling 
pathway were detected via Western blotting at 48 hours post-transfection. (B) The 
culture supernatant was collected at 24 hours post-transfection and used to measure 
IFN-I using a luciferase assay with HEK293 cells with the construct of the luciferase 
reporter gene under the control of IRSE promoter. (C) The secreted IFN-b was 
measured with ELISA at 24 hours post-transfection. Data were and normalized to b-
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Figure 8. IFN-I production was enhanced in hepatocytes infected with rt269I. 
(A-C) The culture supernatant was collected at 24 hours post-transfection and used 
to measure IFN-I. pHBV-1.2x-mock, rt269L, and rt269I plasmid DNA (genotype C) 
were transfected into the Huh 7 (A) and Huh 7.5 cells (B). (C) pHY92-1.1x-HBV-
rt269I (genotype A), 1.2x-rt269L (genotype C), and 1.2x-rt269I (genotype C) 
plasmid DNA were transfected into the HepG2 cells and the IFN-I levels were 
compared among the groups. (D) HBV DNA were transfected into mouse hepatoma 
cell Hepa1c1c-7, and mouse IFN- b in the supernatants were measured by ELISA. 
These data were normalized with b-Galactosidase assay. Data represent mean±S.D. 
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5. The reduced replication capacity and enhanced IFN-I expression of 
rt269I were also proved in two HBV infection models. 
To determine whether the different replication capacity between rt269L and 
rt269I could be reproduced in HBV virion infection assays, HepaRG and HepG2-
hNTCP-C4 which have been widely used for the HBV infection models were used 
[53, 54]. In HepG2-hNTCP-C4 cells, intracellular HBV DNA level was also 
significantly increased in rt269L HBV infected cells compared with that of rt269I 
HBV infected cells on day 3 (Figure 9A). In addition, rt269I-HBV-infected HepG2-
hNTCP-C4 cells showed lower cccDNA level compared with rt269L-HBV-infected 
cells on day 5 (Figure 9B). Futhermore, the secreted HBsAg was more elevated in 
rt269L infected group than rt269I and this pattern was maintained until day 5 after 
infection (Figure 9C). Consistently, extracellular HBV DNA level was also 
increased in rt269L HBV infected cells compared with that of rt269I HBV infected 
cells on day 3 (Figure 9D). The different replication capacities from infection 
between rt269L and rt269I HBV were further verified in HepaRG cells. Intracellular 
HBV DNA level was greatly increased in rt269L versus rt269I HBV infected group, 
and the most distinct difference between two groups was shown on day 2 (Figure 
9E). Reduced cccDNA level, shown in rt269I-HBV infected HepG2-hNTCP-C4 
cells, was also reproduced in HepaRG cells on day 3 (Figure 9F). Furthermore, IFN-
I secretion levels were measured by an ISRE promoter-luciferase assay. As shown 
in transient transfection system, rt269I-infected-HepG2-hNTCP-C4 cells and –
HepaRG cells secreted larger amount of IFN-I compared with rt269L-infected cells 
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on Day 5 and day 0, respectively (Figure 9G and H). Together, I also proved that 
rt269I leads to reduced HBV replication and enhanced IFN-I production in HBV 
virion infection model system, compared to rt269L. 
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Figure 9. The reduced replication capacity of rt269I was shown in HBV 
infection models. (A-D) rt269L- or rt269I- HBV variant infection of HepG2-
hNTCP-C4 cells. (A) Intracellular HBV DNA level were evaluated using qPCR on 
day 1, 3, and 5. (B) HBV cccDNA level was measured in HepG2-hNTCP-C4 cells 
infected by each HBV variant on day 5. (C) HBsAg secretion in the supernatant of 
infected cells were measured using ELISA on day 1, 3, and 5. (D) Extracellular HBV 
DNA level were evaluated using qPCR on day 3.  (E and F) rt269L- or rt269I- 
HBV variant infection of HepaRG cells. (E) Intracellular HBV DNA level was 
measured using qPCR on day 0 and 2. (F) HBV cccDNA level was evaluated in 
HepaRG cells infected by each HBV variant on day3. (G and H) The secreted IFN-
I in HepG2-hNTCP-C4 (G) and HepaRG cells (H) infected by each construct was 
measured using luciferase reporter assay on Day 5 and day 0, respectively. Data 
represents mean ± S.D. of three independent experiments. One- and two-way 
ANOVA were used. *p<0.05, **p<0.01, ***p<0.001.   
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6. The replication of rt269I was inhibited via STING- IFN-I axis. 
Since the secretion of IFN-I exerts antiviral effects against HBV [55, 56], the 
above finding showed that IFN-I was produced in the cells transfected rt269I. 
Therefore, I checked whether replication inhibition found in rt269I depends on IFN-
I signaling. I found that the decreased HBsAg and HBeAg level in rt269I were 
neutralized or even reversed when the IFN-I signal was blocked via IFNAR2 
neutralization at 48 hours post-transfection (Figure 10A). To further check IFN-I 
signal dependence of rt269I replication, JAK-STAT pathway was inhibited using 
AZD1480. As shown in IFNAR2 neutralization, the inhibition of HBsAg and 
HBeAg level in rt269I was reversed by inhibition of JAK-STAT pathway at 48 hours 
after transfection (Figure 10B). Furthermore, I found that the siRNA mediated 
knockdown of STING, but not scramble could lead to reversion of inhibition on 
HBV replication or HBsAg secretion as found in the rt269I type at 48 hours post-
transfection (Figure 10C). Together, these results indicated that rt269I leads lower 
levels of HBV replication via STING- IFN-I-axis in hepatocytes. 
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Figure 10. The replication inhibition found in rt269I was mediated via STING-
IFN-I axis. (A) IFNAR2 was blocked using anti-IFNAR2 antibody (10 µg) and 
HBV-encoding DNA and pSV-b-Galactosidase were transiently transfected into 
HepG2 cells. HBsAg and HBeAg in the presence of isotype or anti-IFNAR2 
antibody were measured using ELISA at 48 hours post-transfection. (B) HepG2 cells 
pre-treated with AZD1480 (5 µM) for 2 hours were transfected with HBV DNA 
pSV-b-Galactosidase and constantly treated with AZD1480. HBsAg and HBeAg 
were measured using ELISA at 48 hours post-transfection. (C) HBV DNA constructs 
and pSV-b-Galactosidase were co-transfected with either STING or scramble siRNA 
into HepG2 cells. The HBeAg levels and HBV virions were analyzed using ELISA 
and qPCR, respectively at 48 hours post-transfection. Data were normalized with b-
Galactosidase enzyme assay, and represents mean ± S.D. of three independent 
experiments. One- and two-way ANOVA were used. *p<0.05, **p<0.01, ***p<0.001. 
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7. rt269I enhanced mitochondrial stress mediated IFN-I production and 
heme oxygenase (HO)-1. 
As bilirubin is one of the final byproducts of inducible HO-1 [57], the clinical 
data showing higher levels of bilirubin in serum of patients with rt269I (Table 1) 
also suggest that rt269I could enhance HO-1 expression. As expected, the expressed 
HO-1 significantly increased in the transcription and translation levels in cells with 
rt269I (Figure 11A and B). Previously, HO-1 has been reported to be induced by 
mitochondrial stress or ROS [58]. Thus, I assessed whether mitochondrial ROS 
(mtROS) could be enhanced in HepG2 cells infected with rt269I. Although both 
groups showed similar cytosolic ROS levels (data not shown), enhanced mtROS 
levels were found in cells with rt269I at 24 hours post-transfection (Figure 12A 
and B), suggesting that rt269I versus rt269L led to enhanced mitochondrial stress. 
To assess whether or not this effect is specific to genotype C, I compared mtROS 
production in HepG2 cells between two types of genotype C, rt269L and rt269I, and 
the wild type of genotype A with Pol of rt269I type via confocal analysis using 
MitoSox. Of these, genotype C-rt269I produced the strongest mtROS, suggesting 
that the enhancing trait of mtROS found in rt269I may also be specific to genotype 
C at 24 hours after transfection (Figure 12C). It has been reported that mtROS can 
cause oxidative mitochondrial DNA damage, resulting in increased mitochondrial 
8-OHdG that is indicative of DNA damage [59]. I consistently observed that the 
quantification of 8-OHdG significantly increased in cells infected with rt269I at 48 
hours post-transfection (Figure 13A). Next, I assessed if mtROS could act as 
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upstream signaling of enhanced IFN-I and HO-1 induction induced by rt269I via 
treatment of MitoTEMPO, a mitochondria-targeted antioxidant. The treatment of 
MitoTEMPO abrogated the increased IFN-I induced by rt269I at 24 hours post-
transfection (Figure 13B). Furthermore, the elevated HO-1 mRNA levels induced 
by rt269I were also completely abrogated by MitoTEMPO treatment at 24 hours 
post-transfection (Figure 13C). Together, these results indicated that rt269I 
infections cause mitochondrial stress and the subsequent cytosol release of oxidized 
mtDNA, resulting in enhanced production of IFN-I and HO-1 in hepatocytes. 
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Figure 11. HepG2 cells enhanced HO-1 in transcription and translation level 
against rt269I infection. HepG2 cells were transfected with HBV DNA and pSV-
b-Galactosidase, and HO-1 production was assessed. (A) Transcription level of HO-
1 was determined using qRT-PCR at 24 hours after transfection. (B) HO-1 protein 
was detected via Western blotting and actin was used as a control. Data were 
normalized by b-Galactosidase assay, and represent mean±SD of three independent 
experiments. *p<0.05, **p<0.01, and ***p<0.001. 







































































rt269I rt269L Mock 
 - 49 - 
Figure 12. rt269I induced mitochondrial reactive oxygen species production. 
pHBV-1.2x-rt269L and -rt269I were co-transfected with pSV-b-Galactosidase into 
HepG2 cells, and mitochondrial stress was assessed. (A and B) Mitochondrial ROS 
was stained with MitoSOX (5 µM) and analyzed by flow cytometry (A) and confocal 
microscope (B), followed by transfection for 24 hours. (C) The HepG2 cells were 
transfected with pHY92-rt269I (genotype A), 1.2x-rt269L (genotype C), and 1.2x-
rt269I (genotype C) plasmid DNA. Data were normalized by b-Galactosidase assay, 
and represent mean±SD of three independent experiments. *p<0.05, **p<0.01, and 
***p<0.001. 
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Figure 13. rt269I caused mitochondrial stress in infected hepatocytes. (A) 
HepG2 cells were co-transfected with HBV DNA and pSV-b-Galactosidase, and 8-
OHdG was detected using ELISA. (B and C) MitoTEMPO (100 µM) was 
administrated to the transfcted cells. (B) IFN-I levels were assessed using an IRSE-
luciferase assay at 24 hours after transfection. (C) qRT-PCR analysis of HO-1 
mRNA levels were evaluated using qRT-PCR at 24 hours after transfection. Data 
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8. rt269I enhanced iNOS dependent NO production. 
 It was previously reported that HBV infections could lead to nitric oxide (NO) 
mediated by inducible nitric oxide synthase (iNOS), which causes the inhibition of 
viral replication [60]. Thus, I assessed iNOS dependent NO production between 
rt269I and rt269L. In an in vivo mouse model, the transcription of iNOS was 
significantly enhanced in rt269I compared to rt269L on 3 days post-injection (Figure 
14A). In in vitro systems of transfected HepG2 cells, rt269I led to enhanced iNOS 
expression via Western blotting at 48 hours post-transfection (Figure 14B). The 
secreted NO measured using ELISA was also significantly increased in rt269I at 24 
hours post-transfection (Figure 14C). In addition, to better understand the antiviral 
effects of NO, the viral replication of both types was also assessed after treatment 
with iNOS inhibitor, Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME). 
Treatment with L-NAME restored decreased HBsAg and HBeAg levels in both 
rt269I and rt269L types, but its effect was more pronounced in rt269I, suggesting 
that the lowered replication shown in rt269I may be in part due to its enhanced NO 
production at 24 hours post-transfection (Figure 15A). It has been reported that IFN-
I can regulate iNOS dependent NO production as its upstream signal [24]. To further 
verify whether iNOS induction found in rt269I is dependent on IFN-I signaling, the 
iNOS expression levels of both types were analyzed from infected HepG2 cells after 
blocking IFNAR2. The increased transcription levels of iNOS found in rt269I were 
abrogated by blocking IFNAR2 at 24 hours post-transfection (Figure 15B). 
Together, the data indicated that rt269I could lead to enhanced iNOS dependent NO 
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production via IFN-I signaling, contributing to disease progression in chronic 
patients with genotype C infections. 
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Figure 14. rt269I enhanced iNOS dependent NO production. (A) The HBV 
constructs were injected with hydrodynamic tail vein into C57BL/6 mice (n=5). 
Transcription levels of iNOS in hepatocytes were determined using qPCR and were 
normalized with 18S rRNA on 3 days post-injection. (B and C) HepG2 cells were 
transfected with HBV construct and pSV-b-Galactosidase was co-transfected to 
normalization. (B) iNOS synthesis was detected via Western blot analysis at 48 hours 
after transfection. (C) Poly(I:C) was co-transfected with HBV DNA and the secreted 
NO2- and NO3- were measured using ELISA at 24 hours post-transfection. One-way 
ANOVA were used. *p<0.05; **p<0.01; ***p<0.001; ns, not significant. 
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Figure 15. rt269I enhanced iNOS dependent NO production in IFN-I dependent 
manner. (A) HepG2 cells pre-treated with L-NAME for 2 hours were transfected 
with HBV DNA and constantly treated with L-NAME. The secreted HBsAg and 
HBeAg were detected by ELISA at 24 hours. (B) IFN-I signaling was blocked by 
anti-IFNAR2 antibody (5 µg) for 12 hours and iNOS gene expression was 
determined using qRT-PCR at 24 hours after transfection. Data are shown as 
mean±SD. One- and two-way ANOVA were used. *p<0.05; **p<0.01; ***p<0.001; 
ns, not significant. 
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DISCUSSION 
 
Of 10 different HBV genotypes, genotype C and genotype B are responsible 
for the majority of HBV infections in endemic Asian countries [40]. In particular, it 
has been reported that most HBV infections in South Korea are due to genotype C 
[61], which may be a major reason for the lower response of IFN therapy [62] or NA 
therapy [63], the higher level of disease progression [64], and the higher prevalence 
of occult infection via vertical transmission [65, 66], observed in Korean CHB 
patients compared to patients in other areas. The current study investigated the 
virological or clinical factors and modulating capacity of antiviral IFN-I innate 
immunity between rt269L and rt269I in HBV genotype C infections. There are some 
noteworthy findings.  
The clinical data using a Korean cohort proved that rt269L and rt269I 
showed distinct clinical or virological traits in HBV replication, HBsAg production, 
HBeAg serostatus, and biliverdin production (Table 1). This strongly suggests that 
there may be differences in modulating antiviral IFN-I production between rt269L 
and rt269I. Given a previous report indicating that the better response of genotype B 
than that of genotype C infections in IFN-α therapy was attributed to a higher level 
of HBeAg seroconversion via IFN-α mediated preC mutations [67], rt269I versus 
rt269L, more related to lower HBV replication or the HBsAg level and more related 
to HBeAg negative serostatus was expected to lead to enhanced IFN-I production. 
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Furthermore, a higher level of bilirubin, which is one of the final products of IFN-I 
mediated HO-1 metabolism, was also found in patients with rt269I type, further 
supporting the aforementioned findings. 
The further epidemiologic data showed that HBeAg seronegative status 
observed in patients with rt269I was due to a higher frequency of preC mutations (G 
to A at 1896) induced via IFN-I mediated APOBEC3G (Table 4 and Figure 6). This 
suggests that longer durations of HBeAg positive stages and lower levels of preC 
mutation frequency observed in patients with genotype C than that of genotype B 
infections [40] may be due to the presence of rt269L only in patients with genotype 
C. Actually, the further mechanism study showed that rt269L could produce lower 
levels of IFN-I production than rt269I, leading to a lower expression of ISGs 
including APOBEC3G in in vitro and in vivo systems, further supporting the 
epidemiological findings. The epidemiologic data also showed that rt269L (63%) 
was more prevalent than rt269I (37%) in the Korean cohort, unlike other areas 
showing more prevalence of rt269I versus rt269L (rt269I vs rt269L: 57% versus 
43%). This suggests that rt269L showed not only high replication factors such as 
HBeAg, HBsAg, and HBV DNA level but also low preC mutation frequencies. 
These features of rt269L can be indicated with characteristics of genotype C, which 
was not shown in other genotypes. In addition, I suggest it may have a merit in 
infections into hosts via perinatal or vertical routes, contributing to chronic infections 
as a major type in South Korea. It is tempting to speculate that the higher prevalence 
of rt269L may contribute to some unique clinical traits found in South Korean CHB 
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patients, including the frequent failure of IFN-α therapy or NA treatments [62, 63] 
and the higher prevalence of occult HBV infections via vertical routes [65, 66]. 
However, this issue demands further investigation in the future. 
The mechanism study indicated that distinct IFN-I production between 
rt269L and rt269I was attributed to different induction capacity of mitochondrial 
stress (Figure 12). Thus, rt269I versus rt269L can lead to enhanced production of 
mtROS and oxidized mtDNA, resulting in induced IFN-I production via cytosolic 
DNA sensing through the STING-IRF3 dependent pathway. To date, distinct 
capacity of mitochondrial stress induced by HBV genotypes, polymorphisms, or 
mutations has not been elucidated. HBV Pol was recently reported to interfere with 
antiviral IFN-I production through DNA sensing via the inhibition of STING 
polyubiquitination [36]. Thus, the functional difference in Pol due to SNP could 
contribute to differences in the two types of mitochondrial stress mediated IFN-I 
production. However, the molecular details regarding this issue remain to be 
elucidated in the future. 
I found enhanced HO-1 expression and iNOS dependent NO production as 
a downstream pathway of IFN-I in rt269I. The enhanced HO-1 expression in rt269I 
exerted anti-HBV effects via the inhibition of virion capsid formation, in line with 
previous reports showing the anti-HBV effects of HO-1 [68]. It has also been 
reported that iNOS dependent NO production as another downstream pathway of 
INF-I could play a pivotal role in inflammatory responses and disease progression 
in the liver, including fibrosis and cirrhosis [24]. I also found enhanced production 
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of iNOS and NO in HepG2 cells transfected with rt269I (Figure 14), in line with the 
clinical data showing that patients with rt269I type infections were more related to 
disease progression. Enhanced iNOS and NO could also increase the frequency of 
preC mutations shown in rt269I, leading to HBeAg negative infections in chronic 
patients. The iNOS dependent NO production and mtROS production can 
synergistically exert apoptotic cell death in the liver, also facilitating the progression 
of liver diseases [69], further supporting the hypothesis regarding the contribution of 
rt269I to disease progression. (Figure 16). 
The finding showing rt269L versus rt269I type led to enhanced HBV 
replication via inhibiting IFN-I production via STING-IFN-I axis is contrast to that 
reported by Ahn et al [70], previously. Maybe, the difference between two studies 
may be due to use of HBV genome plasmid from different patients with distinct 
genome sequences or difference of used cell lines. The pHBV-1.2x (GenBank 
accession No. AY641558) plasmid construct used in this study has no special 
mutations affecting HBV virology and virulence and have been widely used for 
genotype C mutation analysis and virulence studies [49, 71-73]. Furthermore, 
together the HBV genome transient study into diverse human hepatocytes and mouse 
hepatoma cell lines, the in vivo hydrodynamic injection study, in vitro HBV virion 
infection study and even the clinical data consistently supported enhanced HBV 
replication of rt269L versus rt269I type.  
In conclusion, the data showed that rt269I could contribute to HBeAg 
negative infections and liver disease progression in CHB patients with genotype C 
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infections via mitochondrial stress mediated IFN-I production. In addition, enhanced 
iNOS dependent NO production induced by rt269I could also provide an additive 
role in disease progression. Furthermore, the finding could also provide likely 
explanation into characteristic features of genotype C with higher frequency of 
rt269L type, including longer durations of HBeAg positive stages and higher 
infectivity (Figure 16). 
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Figure 16. Schematic presentation indicating distinct mitochondrial stress mediated 
IFN-I production and its distinct contribution to disease progression in chronic 
patients with genotype C infections between rt269L and rt269I. In contrast to rt269L, 
rt269I infection in genotype C induced mitochondrial ROS production, which led to an 
increased release of oxidized DNA into the cytosols of the infected hepatocytes. Sensing 
the oxidized DNA exposed to cytosol via the cGAS-STING pathway could lead to IFN-I 
production. Enhanced INF-I production in rt269I could exert several biological activities. 
First, it can lead to the increased inhibition of HBV replication via the inhibition of capsid 
formation by HO-1 production. Second, IFN-I mediated enhanced expression of 
APOBEC3G and iNOS can lead to HBeAg negative infection and liver disease progression 
via frequent generation of preC mutations at 1896 (G to A). Thus, rt269L can contribute 
to HBeAg negative infection and disease progression in chronic patients infected with 
genotype C via mitochondrial stress mediated enhanced INF-I production.  
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국문초록 
 
B 형 간염 바이러스 유전자형 C 의 역전사효소 내 rtL269I 
변이주의 제 1 형 인터페론 신호전달을 통한  







B 형 간염 바이러스는 세계적으로 심각한 감염성 질환을 유발하며, 특히 
B 형 간염 바이러스에 의한 만성 감염은 생명을 위협하는 간질환을 일으킨다. 
그 중 유전자형 C 는 다른 유전자형에 비해 높은 병원성, 항바이러스제제 
치료의 어려움, 인터페론 알파 치료의 저항성 및 간질환 악화의 급속한 진행 
등의 특성이 관찰되었다. 이러한 특성은 유전자형 C 에서만 발견되는 여러 
유전자 변이주 및 유전자 다형성에 기인할 가능성을 제시하는 연구가 
보고되었으나, 특성과 관련된 근본적인 기전은 여전히 분명하게 밝혀진 바 
없다. 본 연구에서는 유전자형 C 에서 HBV 중합효소 내 역전사 
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효소 rt269L 부위의 두가지 다형성 (rt269L 과 rt269I) 사이의 제 1 형 
인터페론 (IFN-I)을 조절하는 특성과 감염 환자의 임상적 요인을 확인하였다. 
이를 위하여 국내 유전자형 C rt269L과 rt269I 에 감염된 환자 220명 사이의 
임상적 요인을 비교하였으며, 감염환자 및 GenBank 데이터 베이스를 
이용하여 두 다형성 사이의 preC 돌연변이 빈도를 분석하였다. 또한 임상적 
특성의 원인을 규명하기 위하여 C57BL/6 마우스 및 간암세포 모델에서 
감염시킨 후 바이러스 복제 양상, 제 1 형 인터페론 신호 기전 및 
미토콘드리아 스트레스, 활성질소 등을 비교 관찰하였다.  
본 연구의 임상 데이터를 통하여 rt269I 변이주가 rt269L 에 비하여 혈청 내 
외피항원 (HBeAg) 음성감염, 낮은 수준의 HBV DNA 와 표면항원 (HBsAg), 
그리고 질병의 악화를 야기하는 것을 확인하였다. 이러한 rt269I 감염에 의한 
외피항원 음성감염은 preC 내 1896 번째 뉴클레오티드가 구아닌에서 
아데노신으로 돌연변이가 생겨 일어나는 것임을 알 수 있었다. 또한 시험관 
내 및 생체 내 연구에서는 rt269I 가 미토콘드리아 스트레스 매개 제 1 형 
인터페론 생성을 유도하여 힘옥시게나제 (heme oxygenase)-1 의 발현을 
증가시키고, 그 결과 HBV 복제를 감소시킬 수 있다는 것을 확인하였다. 또한, 
rt269I 변이주가 제 1 형 인터페론 의존적인 방식으로 산화질소활성효소 
(inducible nitric oxide synthase) 매개 활성질소 생산을 향상시킬 수 있다는 
것을 발견하였다.  
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이 연구를 통해 HBV 중합효소 내 역전사효소 부위에는 유전자형 C 에서만 
발견되는 rt269L과 rt269I 두가지 다형성이 있음을 확인하였다. 뿐만 아니라, 
이 연구의 결과는 rt269I 변이주가 미토콘드리아 스트레스 매개를 통해 제 
1 형 인터페론을 생산하고, 이 기전이 만성감염 환자에서 외피항원 
음성감염과 간 질환 악화에 영향을 줄 수 있음을 알 수 있었다. 
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스트레스, 제 1 형 인터페론 
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